ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 320 filers reported holding ROYALTY PHARMA PLC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $46,886 | -61.3% | 1,778 | -55.4% | 0.00% | -70.0% |
| Q1 2024 | $121,116 | +23.7% | 3,988 | +14.4% | 0.01% | +25.0% |
| Q4 2023 | $97,950 | +309.6% | 3,487 | +295.8% | 0.01% | +300.0% |
| Q3 2023 | $23,911 | +239.6% | 881 | +284.7% | 0.00% | +100.0% |
| Q2 2023 | $7,040 | -62.4% | 229 | -55.9% | 0.00% | -50.0% |
| Q1 2023 | $18,700 | +100.5% | 519 | +119.9% | 0.00% | +100.0% |
| Q4 2022 | $9,327 | -6.7% | 236 | -5.2% | 0.00% | 0.0% |
| Q3 2022 | $10,000 | -33.3% | 249 | -32.2% | 0.00% | -50.0% |
| Q2 2022 | $15,000 | +7.1% | 367 | -1.9% | 0.00% | 0.0% |
| Q1 2022 | $14,000 | +40.0% | 374 | +48.4% | 0.00% | +100.0% |
| Q4 2021 | $10,000 | +400.0% | 252 | +404.0% | 0.00% | – |
| Q3 2021 | $2,000 | -81.8% | 50 | -81.3% | 0.00% | -100.0% |
| Q2 2021 | $11,000 | – | 267 | +8800.0% | 0.00% | – |
| Q1 2021 | $0 | – | 3 | 0.0% | 0.00% | – |
| Q4 2020 | $0 | – | 3 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
| Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
| Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
| Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
| Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
| Brown University | 621,759 | $24,224,000 | 5.93% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
| Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
| Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |